CN105232526A - Application of medicine containing catechin to preparation of antibacterial medicines - Google Patents
Application of medicine containing catechin to preparation of antibacterial medicines Download PDFInfo
- Publication number
- CN105232526A CN105232526A CN201510670008.3A CN201510670008A CN105232526A CN 105232526 A CN105232526 A CN 105232526A CN 201510670008 A CN201510670008 A CN 201510670008A CN 105232526 A CN105232526 A CN 105232526A
- Authority
- CN
- China
- Prior art keywords
- catechin
- medicine
- antibacterial medicines
- dosage form
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides application of a medicine containing catechin shown in formula (I) or catechin polymorphs to preparation of antibacterial medicines. Through experiment research, the catechin is wide in antibacterial spectrum and has exact inhibiting effect on various pathogenic microorganisms such as staphylococcus aureus, escherichia coli, candida albicans, pseudomonas aeruginosa and hemolytic streptococcus; meanwhile, the catechin has good selectivity and has no irritation to normal flora and vagina mucosa, thereby being promising in application prospect on preparation of the antibacterial medicines. Formula (I).
Description
Technical field
The invention belongs to field of medicaments, especially, relate to the medicine comprising catechin, prepare the purposes in antibacterial medicines.
Background technology
The natural warm and humid profit of female sex organ, easy cooperating microorganisms.Under normal circumstances, can protective action be played by human body from thermotectonics and chemical environment, thus avoid pathological changes.On the one hand, external genital both sides labium majus closes up coverage vaginal orifice naturally, makes inoculating microbe be difficult to enter; In intravaginal, due to the effect of pelvic floor muscles, vagina front and rear wall is close to, and vaginal orifice closes, and can prevent extraneous pollution to a certain extent.On the other hand, under estrogenic impact, the continuous metabolism of vaginal epithelial cell, hypertrophy are thickening, add the withstand force to pathogen; Meanwhile, under the effect of bacterium vaginae, the glycogen be rich in vaginal epithelial cell can be analyzed to lactic acid, to maintain the normal sour environment of vagina, the pathogen being adapted to breed in mild alkaline conditions is suppressed.Therefore, though the intravaginal of healthy women has some antibacterials to exist, usually do not cause inflammation.
Under normal circumstances, intravaginal is preponderated with bacterium vaginae, and also have a small amount of anaerobe, mycoplasma and candidiasis, above-mentioned flora forms certain ecological balance.But, when body immunity is low, endocrine hormone changes, or foeign element is as tissue injury, sexual intercourse, when destroying the ecological balance of vagina, these permanent floras may cause vaginal infection, and the pathogenic microorganism coming from the external world also may be availed oneself of the opportunity to get in.In addition, with factors such as age growth, childbirths, vagina can relax gradually, also can increase the risk that inoculating microbe invades.
When there is this type of gynaecopathia, except relying on self immune system, usually should coordinate Drug therapy, such as, can take antibiotic orally, external antibacterial medicines etc.Be different from intracorporeal organ infection because this type of infects, its disease locus is in body surface, and therefore external used medicine curative effect is more direct.The vagina antibacterial medicines of prior art, two large classifications can be divided into, wherein a class take antibiotic as the antibacterial medicines of effective ingredient, this type of drug effect is very fast, but easily there is toleration, and not there is selectivity to the suppression of microorganism, therefore after drug withdrawal, need the long period to rebuild vaginal microbial flora, in the process subinfection more easily occurs; Another kind of antibacterial medicines is effective ingredient with Chinese medicine composition, it is advantageous that less to skin irritation, there is not microorganism tolerance phenomenon, but defect is that some drugs uncertain therapeutic efficacy is cut and onset is slower.
Catechin also known as cachou extract, tea tannin.For the derivant of flavonol, molecular formula C15H14O6, in colourless crystallization shape solid, can be water-soluble; Its aqueous solution is heated or in the presence of a mineral acid, easily aggregates into amorphous tannin.In prior art, there are some researches show that catechin has the effect such as antioxidation, regulating lipid metabolism, be therefore used as slimming medicine and antiaging agent, report that catechin has the effect such as blood pressure lowering, blood sugar lowering in addition in addition.There is not the report seen and have catechin monomers compound to have bacteriostasis in prior art, more have no the report being prepared into vagina antibacterial medicines.
Summary of the invention
The present invention is intended to in prior art, the technological deficiency that Antimicrobial drug choice is poor, therapeutic domain is narrower, medicine exists side effect etc., provides effective, without the technical scheme of obvious adverse reaction antibacterials, is specially:
The invention provides a kind of antibacterial medicine, comprise catechin, shown in (I):
Further, described antibacterial medicines is the medicine suppressing pathogen in body;
Further, described antibacterial medicines is the medicine suppressing intravaginal pathogen;
Further, described antibacterial medicines is the medicine reducing intravaginal pathogen quantity;
Further, antibacterial action of the present invention comprises the effect of the multiple pathogenic microorganisms to staphylococcus aureus, escherichia coli, Candida albicans, bacillus pyocyaneus, Hemolytic streptococcus etc.
On the other hand, for catechin structural instability, easily there is the technological deficiency that character changes, affects drug effect, present invention also offers a kind of catechin microcrystal, stable antibacterial medicine can be provided.This Microcrystal catechin uses Cu-K α radiation, as shown in table 1 with the X-ray powder diffraction spectral signature that 2 θ angles represent:
Table 1 catechin X-ray powder diffraction spectral signature
| 2 θ values | D value | FWHM | I/I 0％ |
| 15.120 | 5.8584 | 0.118 | 58 |
| 23.740 | 3.7448 | 0.212 | 100 |
On the one hand, the content of catechin in its pharmaceutical composition is 0.1-95 % by weight; Preferred, catechin content in its pharmaceutical composition is 0.1-75 % by weight; Preferred, catechin content in its pharmaceutical composition is 0.1-50 % by weight; Preferred, catechin content in its pharmaceutical composition is 0.1-25 % by weight; Preferred, catechin content in its pharmaceutical composition is 0.1-15 % by weight; Preferred, catechin content in its pharmaceutical composition is 0.1-10 % by weight.
The present invention, by pharmaceutically acceptable to catechin and one or more excipient and/or carrier being combined, makes any dosage form being suitable for human or animal and using.Catechin or the pharmaceutical composition containing it can administrations in a unit, and route of administration can be intestinal or non-bowel, as oral, intravenous injection, intramuscular injection, subcutaneous injection etc.Form of administration can be liquid dosage form, solid dosage forms or semisolid dosage form.Liquid dosage form can be solution (comprising true solution and colloid solution), Emulsion (comprising o/w type, w/o type and emulsion), suspensoid, injection (comprising aqueous injection, injectable powder and transfusion) etc.; Solid dosage forms can be tablet (comprising ordinary tablet, enteric coatel tablets, buccal tablet, dispersible tablet, chewable tablet, effervescent tablet, oral cavity disintegration tablet), capsule (comprising hard capsule, soft capsule, enteric coated capsule), granule, powder, micropill, drop pill, the agent of gas (powder) mist, spray etc.
Catechin can be made ordinary preparation, also make is slow releasing preparation, controlled release preparation, targeting preparation and various particulate delivery system.
Preferably, in above technical scheme, described medicine is medicine for external use; Described medicine includes but not limited to mucosa delivery dosage form; Preferred further, described dosage form is vaginal mucosa form of administration, vaginal mucosa administration has a lot of advantage in whole body therapeutic, such as first pass effect can be avoided, reduce protease to the hydrolysis of medicine, penetrating agent is selected from nonionic surfactant, comprises cholate, glyceride, organic acid, polidocanol, lecithin, palmitoyl chloride carnitine etc.; Preferred, described dosage form comprises powder, cream, ointment, gel, Emulsion, lotion, suppository, effervescent tablet or liniment etc.According to its dosage form, pharmaceutical composition of the present invention can apply various pharmaceutical field customary adjuvant, comprises one or more in excipient, transdermal agent and pruritus.Described excipient is this area customary adjuvant, is preferably one or more in liquid Paraffin, glycerol monostearate vinegar, stearic acid, polyvinyl alcohol, carbomer and carboxymethyl cellulose.Described transdermal agent is this area customary adjuvant, in order to promote that skin absorbs, is preferably sodium lauryl sulphate and/or azone.Described pruritus is this area customary adjuvant, is preferably Oleum menthae and/or Borneolum Syntheticum.Except above-mentioned adjuvant, pharmaceutical composition of the present invention also can contain the active constituents of medicine of antibacterial action, uses as compound preparation.
Concrete pharmacological evaluation test result is as follows:
(1) bacteriostasis of catechin
1) catechin is to the In Vitro Bacteriostasis effect experimental of Candida albicans: adopt agar method to carry out bacteriostatic experiment, Vitro Experimental Results shows, along with passage of time, catechin has inhibitory action significantly to Candida albicans, catechin aqueous solution effect 5min, to the average bacteriostasis rate of Candida albicans be after 91.24%, 20min to the suppression ratio of Candida albicans up to more than 99%, given the test agent has stronger bacteriostasis to Candida albicans.
2) catechin is to colibacillary In Vitro Bacteriostasis effect experimental: adopt agar method to carry out bacteriostatic experiment, Vitro Experimental Results shows, along with passage of time, catechin has inhibitory action significantly to escherichia coli, catechin aqueous solution effect 10min, be 91.24% to colibacillary average bacteriostasis rate, given the test agent has stronger bacteriostasis to escherichia coli.
3) catechin is to the In Vitro Bacteriostasis effect experimental of staphylococcus aureus: adopt agar method to carry out bacteriostatic experiment, Vitro Experimental Results shows, along with passage of time, catechin has inhibitory action significantly to staphylococcus aureus, catechin aqueous solution effect 2min, namely reach more than 98% to the average bacteriostasis rate of staphylococcus aureus, given the test agent has stronger bacteriostasis to staphylococcus aureus.
4) catechin is to the In Vitro Bacteriostasis effect experimental of bacillus pyocyaneus: adopt agar method to carry out bacteriostatic experiment, Vitro Experimental Results shows, along with passage of time, catechin has inhibitory action significantly to bacillus pyocyaneus, catechin aqueous solution effect 10min, namely reach more than 90% to the average bacteriostasis rate of bacillus pyocyaneus, given the test agent has stronger bacteriostasis to bacillus pyocyaneus.
5) catechin is to the In Vitro Bacteriostasis effect experimental of Hemolytic streptococcus: adopt agar method to carry out bacteriostatic experiment, Vitro Experimental Results shows, along with passage of time, catechin has inhibitory action significantly to Hemolytic streptococcus, catechin aqueous solution effect 5min, namely reach more than 90% to the average bacteriostasis rate of Hemolytic streptococcus, given the test agent has stronger bacteriostasis to Hemolytic streptococcus.
(2) catechin is for the impact of normal flora in body
Adopt agar method to carry out bacteriostatic experiment, Vitro Experimental Results shows, along with passage of time, finds catechin aqueous solution more than effect 20min, is only 3.27%, the bacteriostasis that given the test agent does not have lactobacillus to the average bacteriostasis rate of lactobacillus.
(3) resistance assay of catechin
Total number of bacterial colonies and initial contaminating bacteria detection method is adopted to test, Vitro Experimental Results shows, the total number of bacterial colonies of catechin aqueous solution, coliform, staphylococcus aureus, bacillus pyocyaneus, Hemolytic streptococcus, fungus colony sum conform with the regulations.
(4) catechin is tested for the effect of vaginal mucosa
Adopt Tests For Irritating Effects, carry out mucous membrane irritation experiment, contrast show with blank group animal subject, contamination Zu Ge group is showed no hyperemia, edema, and result display catechin is to the effect of vaginal mucosa nonirritant.
In sum, the present invention has following beneficial effect: catechin has antimicrobial spectrum more widely, can play definite inhibition to the multiple pathogenic microorganism comprising staphylococcus aureus, escherichia coli, Candida albicans, bacillus pyocyaneus, Hemolytic streptococcus etc.; And the inhibitory action of catechin to microorganism has embodied certain selectivity, does not destroy normal flora in human body, reduce the probability of repeated infection; On the other hand, the present invention also demonstrates catechin and has no stimulation to vaginal mucosa, further demonstrates the antibacterial medicines that catechin is particularly suited for acting on vagina.
Detailed description of the invention
For making the object, technical solutions and advantages of the present invention clearly understand, below in conjunction with detailed description of the invention, the present invention is described in more detail.Should be appreciated that, these describe just exemplary, and do not really want to limit the scope of the invention.In addition, in the following description, the description to known features and technology is eliminated, to avoid unnecessarily obscuring concept of the present invention.
Apart from outside definition, technology used in following examples and scientific terminology have the identical meanings generally understood with those skilled in the art of the invention.
Embodiment 1: catechin is tested Candida albicans fungistatic effect
-, equipment
Test strain: to Candida albicans (ATCC10231), China General Microbiological DSMZ provides, the 4th generation.
Test specimen: catechin aqueous solution (concentration 5g/L)
Phosphate buffer (PBS0.03moL/L, pH7.2)
Culture medium: sabouraud's agar.
Two, method
Test basis: GB15979-2002.
Testing conditions: test ambient temperature 20 DEG C, number of repetition 3 times.
Three, experimental result
Fungistatic effect is as shown in the table:
Table 1 catechin is to Candida albicans fungistatic effect experimental result
Note: positive controls bacterium number is 5.35 × 104cfu/mL (4.8 × 104 ~ 5.8 × 104cfu/mL).
Four, conclusion
According to GB15979-2002 " Disposable Sanitary Accessory sanitary standard ", catechin aqueous solution effect 5min, be 91.24% to the average bacteriostasis rate of Candida albicans, given the test agent has stronger bacteriostasis to Candida albicans.
Embodiment 2: catechin is tested escherichia coli fungistatic effect
(-) equipment
Test strain: escherichia coli (8099), preventive medicine academy of science Disinfection examination center provides, the 4th generation
Test specimen: catechin aqueous solution (concentration 3g/L)
Phosphate buffer (PBS0.03moL/L, pH7.2)
Culture medium: nutrient agar.
(2) method
Test basis: GB15979-2002
Testing conditions: test ambient temperature 20 DEG C, number of repetition 3 times
(3) experimental result
Fungistatic effect is as shown in the table:
Table 2 catechin is to escherichia coli fungistatic effect experimental result
Note: positive controls bacterium number is 4.11 × 104cfu/mL (3.76 × 104 ~ 4.38 × 104cfu/mL).
Four, conclusion
According to GB15979-2002 " Disposable Sanitary Accessory sanitary standard ", catechin aqueous solution effect 10min, be 90.27% to colibacillary average bacteriostasis rate, given the test agent has stronger bacteriostasis to escherichia coli.
Embodiment 3: catechin is tested escherichia coli fungistatic effect
One, equipment
Test strain: staphylococcus aureus (ATCC6538), China General Microbiological DSMZ provides, the 4th generation.
Test specimen: catechin aqueous solution (concentration 8g/L)
Phosphate buffer (PBS0.03moL/L, pH7.2)
Culture medium: nutrient agar.
Two, method
Test basis: GB15979-2002
Testing conditions: test ambient temperature 20 DEG C, number of repetition 3 times
Three, experimental result
Fungistatic effect is as shown in the table:
Table 3 catechin is to staphylococcus aureus fungistatic effect experimental result
Note: positive controls bacterium number is 3.67 × 104cfu/mL (3.24 × 104 ~ 4.08 × 104cfu/mL).
Four, conclusion
According to GB15979-2002 " Disposable Sanitary Accessory sanitary standard ", catechin aqueous solution effect 2min, be 98.66% to the average bacteriostasis rate of staphylococcus aureus, given the test agent has stronger bacteriostasis to staphylococcus aureus.
Embodiment 4: catechin is tested lactobacillus fungistatic effect
One, equipment
Test strain: Zhan's formula lactobacillus (ATCC25258), American Type Culture Collecti provides, the 4th generation.
Test specimen: catechin aqueous solution (concentration 10g/L)
Phosphate buffer (PBS0.03moL/L, pH7.2)
Culture medium: MRS culture medium.
Two, method
Test basis: GB4789.35-2010
Testing conditions: test ambient temperature 20 DEG C, number of repetition 3 times
Three, experimental result
Fungistatic effect is as shown in the table:
Table 4 catechin is to lactobacillus fungistatic effect experimental result
Note: positive controls bacterium number is 4.25 × 104cfu/mL (3.88 × 104 ~ 4.51 × 104cfu/mL).
Four, conclusion
The method of inspection according to GB4789.35-2010 " lactobacillus touchstone " defined performs inspection, find catechin aqueous solution effect 20min, be only 3.27% to the average bacteriostasis rate of lactobacillus, given the test agent does not have definite bacteriostasis to lactobacillus.
Embodiment 5: catechin aqueous solution resisting microbial contamination Performance Detection
One, equipment
Laboratory sample: catechin aqueous solution (concentration 5g/L)
Two, method
Test basis: GB15979-2002
Testing conditions: ambient temperature 20 DEG C, relative humidity 40-50%.
Three, experimental result
Fungistatic effect is as shown in the table:
Table 5 microbial contamination testing result
Four, conclusion
The total number of bacterial colonies of catechin aqueous solution, coliform, staphylococcus aureus, bacillus pyocyaneus, Hemolytic streptococcus, fungus colony sum meet the regulation of GB15979-2002 " Disposable Sanitary Accessory sanitary standard ".
Embodiment 6: catechin aqueous solution vaginal mucosa irritation is tested
One, test objective
Detect tested material to the stimulation of laboratory animal vaginal mucosa and intensity.
Two, experiment condition
1, laboratory animal: the female large ear rabbit of regular grade 6, body weight 2.5 ~ 3.0kg, cultivating factory by Beijing Shahe's tonneau experimental animal provides, quality certification SCXK (capital) 2010-00040238286, adapt to 3 days in the room of inspection outward in Animal House, be in a good state of health.
2, experimental animal feeding environment: regular grade Animal Lab., the quality certification number: real accurate No. 004 of the dynamic facility in Tianjin.Temperature 20 ~ 25 DEG C, relative humidity 40 ~ 70%.Feedstuff is provided by Beijing HFK Bio-Technology Co., Ltd., Feed Manufacturing credit number SCXK (capital) 2009-0008.
Three, tested material
Catechin aqueous solution (concentration is 10g/L), takes sample 10g, adds water to 1L, test.
Four, test method
1, test basis: 2.3.5 Tests For Irritating Effects in " disinfection technology standard " (version in 2002).
2, experiment grouping: laboratory animal is divided into contamination group, blank group, often organizes three.
3, operation sequence: before test, inspection Check laboratory animal vaginal orifice has no secretions, hyperemia, edema and other damages.Be that the blunt nosed flexible pipe of about 8cm is connected with the syringe of 2ml by length.Syringe and flexible pipe fill by test solution for subsequent use.Animal faces upward fixing, exposes perineum and vaginal orifice, flexible pipe is gently inserted vagina (4 ~ 5cm) after moistening by test solution, and slowly inject 2ml given the test agent with syringe, extract conduit out, complete contamination.Control animals normal saline does same process.Contaminate latter 24 hours, adopt aeroembolism method to put to death animal, cut open the belly and take out complete vagina, longitudinally cut open, perusal whether hyperemia, edema etc.Then vagina is put into 4% formalin and fix more than 24h, that chooses 3 positions in two ends and central authorities of vagina organizes film-making, and HE dyes, and carries out histopathologic examination's (see table 6).
Five, experimental result
The each laboratory animal vaginal mucosa of perusal is showed no hyperemia, edema, and histopathologic examination's stimulation index is 0.55.
Fungistatic effect is as shown in the table:
Table 6 catechin is to vaginal mucosa irritant reaction scoring experimental result
Six, conclusion
Catechin is to the effect of vaginal mucosa nonirritant.
Embodiment 7: the preparation of catechin lotion
Prescription: catechin microcrystal 10g, sodium chloride 8.5g, PLURONICS F87 1g, distilled water add to 1000ml;
Preparation method: get catechin microcrystal 45g, PLURONICS F87 2g, the two be dissolved in distilled water, make whole dissolving, add sodium chloride and dissolve, adding distil water, to 1000ml, filters, fill and get final product.
Embodiment 8: the preparation of catechin cream
Prescription: 1. catechin 20g, 2. hexadecanol 76.5g, 3. vaseline 180g, liquid paraffin 40g, 5. sodium lauryl sulphate 8.5g, 6. propylene glycol 45g, 7. nipalgin second vinegar 1g, the aseptic double-distilled water that 8. newly boils is some.
Preparation method: first will 2. 3. 4. in water-bath melting obtain solution A, will 5. 6. 7. adding distilled water heating for dissolving obtains solution B, inject solution B after 1. dissolving with appropriate distilled water and obtain solution C, solution A is added in solution C gradually and is stirred to emulsifying, cool.
Above embodiments of the invention have been described in detail, but described content is only preferred embodiment of the present invention, not in order to limit the present invention.All make in application range of the present invention any amendment, equivalent to replace and improvement etc., all should be included within protection scope of the present invention.
Claims (18)
1. an antibacterial medicines, is characterized in that, comprises catechin, and described catechin is such as formula shown in (I):
The content of described catechin in its pharmaceutical composition is 0.1-95 % by weight; Preferred, catechin content in its pharmaceutical composition is 0.1-75 % by weight; Preferred, catechin content in its pharmaceutical composition is 0.1-50 % by weight; Preferred, catechin content in its pharmaceutical composition is 0.1-25 % by weight; Preferred, catechin content in its pharmaceutical composition is 0.1-15 % by weight; Preferred, catechin content in its pharmaceutical composition is 0.1-10 % by weight.
2. antibacterial medicines according to claim 1, is characterized in that, described catechin is Microcrystal catechin.
3. antibacterial medicines according to claim 2, is characterized in that, described Microcrystal catechin uses Cu-K α radiation, and the X-ray Powder Diffraction pattern represented with 2 θ angles has peak in 15.12+/-0.01 and 23.740+/-0.01 place.
4. the antibacterial medicines according to any one of claim 1-3, is characterized in that, described medicine is the medicine suppressing intravaginal pathogen; Preferably, for reducing the medicine of intravaginal pathogen quantity.
5. the antibacterial medicines according to any one of claim 1-3, it is characterized in that, described antibacterial medicines comprises the inhibitory action of the multiple pathogenic microorganisms to staphylococcus aureus, escherichia coli, Candida albicans, bacillus pyocyaneus, Hemolytic streptococcus etc.
6. the antibacterial medicines according to any one of claim 1-3, is characterized in that, the dosage form of described medicine is acceptable any dosage form clinically.
7. antibacterial medicines according to claim 6, is characterized in that, the dosage form of described medicine is medicine for external use; Preferably, be the dosage form of transvaginal mucosa delivery; Preferred, comprise powder, cream, ointment, gel, Emulsion, lotion, suppository, effervescent tablet or liniment.
8. antibacterial medicines according to claim 7, is characterized in that, described medicine is lotion, also comprises pharmaceutically acceptable carrier.
9. antibacterial medicines according to claim 7, is characterized in that, described medicine is unguentum agent, also comprises pharmaceutically acceptable carrier.
10. catechin is preparing the purposes in antibacterial medicines.
11. purposes according to claim 10, is characterized in that, described catechin is Microcrystal catechin.
12. purposes according to claim 10, is characterized in that, described Microcrystal catechin uses Cu-K α radiation, and the X-ray Powder Diffraction pattern represented with 2 θ angles has peak in 15.12+/-0.01 and 23.740+/-0.01 place.
13. purposes according to any one of claim 10-12, is characterized in that, described medicine is the medicine suppressing intravaginal pathogen; Preferably, for reducing the medicine of intravaginal pathogen quantity.
14. purposes according to any one of claim 10-12, it is characterized in that, described antibacterial medicines comprises inhibited medicine such as the multiple pathogenic microorganisms of staphylococcus aureus, escherichia coli, Candida albicans, bacillus pyocyaneus, Hemolytic streptococcus etc.
15. purposes according to any one of claim 10-12, is characterized in that, the dosage form of described medicine is acceptable any dosage form clinically.
16. purposes according to claim 15, is characterized in that, described in the dosage form of described medicine, the dosage form of medicine is medicine for external use; Preferably, be the dosage form of transvaginal mucosa delivery; Preferred, comprise powder, cream, ointment, gel, Emulsion, lotion, suppository, effervescent tablet or liniment.
17. antibacterial medicines according to claim 16, is characterized in that, described medicine is lotion, also comprises pharmaceutically acceptable carrier.
18. antibacterial medicines according to claim 16, is characterized in that, described medicine is unguentum, also comprises pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510670008.3A CN105232526B (en) | 2015-10-15 | 2015-10-15 | Purposes of the drug containing catechin in preparing antibacterial medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510670008.3A CN105232526B (en) | 2015-10-15 | 2015-10-15 | Purposes of the drug containing catechin in preparing antibacterial medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105232526A true CN105232526A (en) | 2016-01-13 |
| CN105232526B CN105232526B (en) | 2018-08-07 |
Family
ID=55030529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510670008.3A Active CN105232526B (en) | 2015-10-15 | 2015-10-15 | Purposes of the drug containing catechin in preparing antibacterial medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232526B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106038477A (en) * | 2016-06-14 | 2016-10-26 | 上海通用药业股份有限公司 | Method for preparing vagina gel containing tioconazole |
| CN106109398A (en) * | 2016-06-14 | 2016-11-16 | 上海通用药业股份有限公司 | A kind of vagina gel containing tioconazole |
| CN109010332A (en) * | 2018-08-06 | 2018-12-18 | 华茗国际健康产业（香港）有限公司 | A kind of inhibiting-bacteria preparation based on crystallite catechin |
| CN110089519A (en) * | 2019-05-08 | 2019-08-06 | 东北大学 | A kind of microbiologic(al) corrosion inhibitor and its application method |
| CN113081881A (en) * | 2020-04-10 | 2021-07-09 | 杭州睿道医药科技有限公司 | Antibacterial and antiviral wash-free hand sanitizer and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102875513A (en) * | 2012-05-17 | 2013-01-16 | 王孝仓 | Microcrystal catechin and preparation method thereof |
-
2015
- 2015-10-15 CN CN201510670008.3A patent/CN105232526B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102875513A (en) * | 2012-05-17 | 2013-01-16 | 王孝仓 | Microcrystal catechin and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 刘强 等: "儿茶素类对h-VRS的体外抗菌活性研究", 《中国抗生素杂志》 * |
| 李强 等: "《新编常用中药有效成分手册》", 31 January 2008 * |
| 董金甫 等: "茶多酚抑菌作用的研究", 《生物学杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106038477A (en) * | 2016-06-14 | 2016-10-26 | 上海通用药业股份有限公司 | Method for preparing vagina gel containing tioconazole |
| CN106109398A (en) * | 2016-06-14 | 2016-11-16 | 上海通用药业股份有限公司 | A kind of vagina gel containing tioconazole |
| CN109010332A (en) * | 2018-08-06 | 2018-12-18 | 华茗国际健康产业（香港）有限公司 | A kind of inhibiting-bacteria preparation based on crystallite catechin |
| CN110089519A (en) * | 2019-05-08 | 2019-08-06 | 东北大学 | A kind of microbiologic(al) corrosion inhibitor and its application method |
| CN110089519B (en) * | 2019-05-08 | 2022-02-11 | 东北大学 | Microbial corrosion inhibitor and use method thereof |
| CN113081881A (en) * | 2020-04-10 | 2021-07-09 | 杭州睿道医药科技有限公司 | Antibacterial and antiviral wash-free hand sanitizer and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105232526B (en) | 2018-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2536264C2 (en) | Topical dermal composition containing salt and sugar as active ingredients for preventing and treating vaginosis, and using it | |
| CN105232526B (en) | Purposes of the drug containing catechin in preparing antibacterial medicines | |
| ES2623382T3 (en) | Vaginal ovule comprising lactic acid | |
| TW200403069A (en) | Antimicrobial agent and antimicrobial composition | |
| US20120245132A1 (en) | Composition Comprising Benzoic Acid in Combination with Organic Acid Preservatives as Active Ingredients and the Use Thereof | |
| CN111449973A (en) | Foaming agent for restoring microecological balance of female vagina and preparation method thereof | |
| CN109985069B (en) | Probiotic compositions and uses thereof | |
| CN108721441A (en) | Gynecological gel | |
| CN110585418A (en) | External use disinfection essential oil emulsion for women and production process thereof | |
| CN102048729B (en) | Preparation for treating vaginitis | |
| MX2007011885A (en) | A method for preventing and/or treating vaginal and vulval infections. | |
| JP2559735B2 (en) | Anti-microbial composition | |
| ES2896680T3 (en) | Glucono delta lactone for the treatment of vaginal fungal infections | |
| EP2643003B1 (en) | Vaginal composition based on alkyl polyglucosides | |
| CN110101655A (en) | A kind of composition repaired uterine neck and prevent bacterial vaginitis | |
| Collier et al. | Further observations on the biological properties of dequalinium (dequadin) and hedaquinium (teoquel) | |
| EP2886117B1 (en) | Topical compositions for the treatment of Gardnerella vaginalis infections | |
| US9408868B2 (en) | Skin external composition comprising a combination of sodium chloride and glucose as active ingredients for treating vaginosis and the use thereof | |
| AU2009247064B9 (en) | Medicinal agent exhibiting antiprotozoal activity to Trichomonas vaginalis in an in-vitro model system | |
| RU2309761C1 (en) | Method for treating chronic relapsing vulvovaginal candidosis | |
| CN114831924A (en) | Urotropine and vaginal local administration preparation of compound thereof and application | |
| US20130108717A1 (en) | Compositions for the treatment of gynaecological disorders | |
| CN105749261A (en) | Composite hydrochloric acid lysozyme vagina tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |